Medexus Pharmaceuticals 将来の成長
Future 基準チェック /56
Medexus Pharmaceuticals利益と収益がそれぞれ年間52.7%と14.2%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に32% 52.7%なると予測されています。
主要情報
52.7%
収益成長率
52.68%
EPS成長率
| Pharmaceuticals 収益成長 | 11.5% |
| 収益成長率 | 14.2% |
| 将来の株主資本利益率 | 32.00% |
| アナリストカバレッジ | Low |
| 最終更新日 | 29 Jun 2026 |
今後の成長に関する最新情報
Recent updates
ナラティブ更新 • Jun 17
MDP: Share Repurchases And New Cell Therapy Rights Will Support Upside
Analysts have modestly adjusted their fair value price target for Medexus Pharmaceuticals stock to CA$8.00, reflecting updated assumptions around revenue growth, profit margins, and future P/E expectations, while keeping the overall valuation level unchanged. What's in the News for Medexus Pharmaceuticals Secured exclusive Canadian rights to commercialize UM171 Cell Therapy, branded as Zemcelpro (dorocubicel) in Europe, through a license and supply agreement with ExCellThera and its subsidiary Cordex Biologics.ナラティブ更新 • Jun 02
MDP: Ongoing Share Repurchases Will Support Upside Potential
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E as the key drivers of the revised valuation. What's in the News Medexus reported an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, with 56 healthcare institutions having granted positive formulary inclusion decisions as of March 31, 2026, and 64 transplant centers having ordered the product for procedures.ナラティブ更新 • Apr 27
MDP: Share Repurchases And Transplant Center Adoption Will Support Upside
Analysts have modestly raised their CA$ price target on Medexus Pharmaceuticals, citing slightly higher modeled revenue growth of 21.21% and a profit margin assumption of 24.84%, while keeping the fair value and discount rate unchanged. What's in the News Medexus provided an operational update on the commercialization of GRAFAPEX (treosulfan) for Injection in the United States, including recent progress with transplant center formulary decisions and ordering activity.ナラティブ更新 • Apr 09
MDP: Share Buyback And Higher Future P E Multiple Will Support Upside
Analysts have adjusted their CA$ price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth, profit margins, and future P/E that refine their outlook on the company’s valuation. What's in the News Medexus Pharmaceuticals completed a share buyback tranche covering 191,900 shares, equal to 0.59% of its shares, between November 20, 2025 and December 31, 2025 (Key Developments).ナラティブ更新 • Mar 26
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have modestly lifted their price target on Medexus Pharmaceuticals to CA$8.00, reflecting slightly higher modeled revenue growth, a small uptick in profit margin assumptions, and a marginally lower future P/E multiple. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares from November 20, 2025 to December 31, 2025, representing 0.59% of its shares, for a total of CA$0.52 million under its previously announced buyback program (Key Developments).ナラティブ更新 • Mar 11
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have raised their CA$ price target on Medexus Pharmaceuticals, citing slightly stronger modeled revenue growth of 19.57% and a profit margin of 27.71%, along with a modestly lower forward P/E of 4.80x in their updated assumptions. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of shares, for CAD 0.52 million under its buyback program announced on November 20, 2025 (Key Developments).ナラティブ更新 • Feb 25
MDP: Share Repurchase And Higher Margin Outlook Will Support Future Upside
Analysts have revised their CA$ price target on Medexus Pharmaceuticals upward, reflecting updated assumptions that include modeled revenue growth of 19.35%, a profit margin of 27.36% and a slightly lower forward P/E of 4.85x. What's in the News Medexus Pharmaceuticals completed a share repurchase of 191,900 shares, representing 0.59% of its outstanding equity, for a total cost of CA$0.52 million under the buyback announced on November 20, 2025 (Key Developments).ナラティブ更新 • Feb 10
MDP: Share Repurchase Plan Will Support Higher Future Shareholder Value
Analysts have modestly adjusted their price target on Medexus Pharmaceuticals, citing updated assumptions around revenue growth of about 17.94%, profit margin of about 25.99% and a future P/E of about 5.10x. Together, these figures inform a refreshed fair value view of US$8.00 per share.ナラティブ更新 • Jan 26
MDP: Share Repurchase Plan Will Support Stronger Future Shareholder Returns
Analysts have lifted their price target on Medexus Pharmaceuticals to US$8.00 from US$8.00, citing slightly higher modeled revenue growth, a modestly stronger profit margin outlook, and a small adjustment to the future P/E assumption. What's in the News Medexus Pharmaceuticals has announced a share repurchase program that allows the company to buy back up to 2,983,650 shares, or 9.2% of its issued share capital, with all repurchased shares set to be cancelled.ナラティブ更新 • Jan 11
MDP: Share Repurchase Program Will Support Stronger Future Shareholder Returns
Analysts have reaffirmed their price target on Medexus Pharmaceuticals at US$8.00, citing updated assumptions for revenue growth, profit margins, and future P/E that adjust their overall outlook while keeping the fair value level unchanged. What's in the News Medexus Pharmaceuticals Inc.分析記事 • Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブ更新 • Dec 16
MDP: Share Repurchase Program Will Drive Stronger Future Shareholder Returns
Analysts have raised their price target for Medexus Pharmaceuticals to approximately $8.00 per share from about $6.00, citing expectations of stronger revenue growth, a substantial improvement in profit margins, and a lower projected future P/E multiple that enhances the stock's valuation appeal. What's in the News Medexus Pharmaceuticals Inc.
ナラティブ更新 • Aug 20
US Transplant Centers Will Drive Specialty Care Adoption
Despite notable improvements in net profit margin and revenue growth forecasts, the consensus analyst price target for Medexus Pharmaceuticals has been revised downward from CA$7.11 to CA$6.71. What's in the News Medexus Pharmaceuticals received approval from US CMS for New Technology Add-On Payment (NTAP) reimbursement for GRAFAPEX™ (treosulfan) for Injection for fiscal year 2026.ナラティブ更新 • Aug 06
US Transplant Centers Will Drive Specialty Care Adoption
The notable increase in Medexus Pharmaceuticals' consensus price target is primarily driven by a significant rise in its future P/E valuation, with fair value revised upward from CA$6.50 to CA$7.11. Valuation Changes Summary of Valuation Changes for Medexus Pharmaceuticals The Consensus Analyst Price Target has risen from CA$6.50 to CA$7.11.分析記事 • May 04
Earnings Tell The Story For Medexus Pharmaceuticals Inc. (TSE:MDP) As Its Stock Soars 28%
Those holding Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares would be relieved that the share price has rebounded 28...
新しいナラティブ • Feb 19
FDA Approval Of GRAFAPEX Will Unlock Market Potential With 7 Years Exclusivity
Successful FDA approval for GRAFAPEX is expected to significantly increase revenue, providing a robust new stream with its granted exclusivity.分析記事 • Jan 19
Investors Appear Satisfied With Medexus Pharmaceuticals Inc.'s (TSE:MDP) Prospects As Shares Rocket 52%
Despite an already strong run, Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have been powering on, with a gain of...分析記事 • Dec 05
After Leaping 31% Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Are Not Flying Under The Radar
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 31% after a shaky period...分析記事 • Nov 05
Is Medexus Pharmaceuticals (TSE:MDP) Using Too Much Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Aug 19
There May Be Reason For Hope In Medexus Pharmaceuticals' (TSE:MDP) Disappointing Earnings
Medexus Pharmaceuticals Inc.'s ( TSE:MDP ) stock was strong despite it releasing a soft earnings report last week. We...分析記事 • Aug 10
Medexus Pharmaceuticals Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Medexus Pharmaceuticals Inc. ( TSE:MDP ) just released its latest quarterly results and things are looking bullish. It...分析記事 • Jul 31
Medexus Pharmaceuticals Inc. (TSE:MDP) Shares Fly 29% But Investors Aren't Buying For Growth
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shareholders have had their patience rewarded with a 29% share price jump in...分析記事 • Jun 15
The Market Doesn't Like What It Sees From Medexus Pharmaceuticals Inc.'s (TSE:MDP) Revenues Yet
When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...分析記事 • Apr 25
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has A Meaningful Debt Burden
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Mar 03
Revenues Working Against Medexus Pharmaceuticals Inc.'s (TSE:MDP) Share Price Following 26% Dive
The Medexus Pharmaceuticals Inc. ( TSE:MDP ) share price has softened a substantial 26% over the previous 30 days...分析記事 • Jan 06
Medexus Pharmaceuticals Inc.'s (TSE:MDP) Shares Leap 89% Yet They're Still Not Telling The Full Story
Medexus Pharmaceuticals Inc. ( TSE:MDP ) shares have had a really impressive month, gaining 89% after a shaky period...分析記事 • Oct 11
Here's Why Medexus Pharmaceuticals (TSE:MDP) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 3/31/2029 | 161 | 42 | N/A | 44 | 4 |
| 3/31/2028 | 139 | 24 | N/A | 30 | 5 |
| 3/31/2027 | 113 | 9 | N/A | 17 | 5 |
| 3/31/2026 | 99 | -2 | 4 | 19 | N/A |
| 12/31/2025 | 99 | 0 | 10 | 17 | N/A |
| 9/30/2025 | 104 | 0 | 13 | 16 | N/A |
| 6/30/2025 | 106 | 1 | 14 | 20 | N/A |
| 3/31/2025 | 108 | 2 | 21 | 24 | N/A |
| 12/31/2024 | 110 | 4 | 20 | 23 | N/A |
| 9/30/2024 | 105 | 2 | 19 | 22 | N/A |
| 6/30/2024 | 109 | 1 | 22 | 23 | N/A |
| 3/31/2024 | 113 | 0 | 18 | 19 | N/A |
| 12/31/2023 | 116 | 6 | 21 | 21 | N/A |
| 9/30/2023 | 119 | 5 | 13 | 13 | N/A |
| 6/30/2023 | 117 | 3 | 6 | 7 | N/A |
| 3/31/2023 | 108 | 1 | -2 | -1 | N/A |
| 12/31/2022 | 100 | -11 | -3 | -2 | N/A |
| 9/30/2022 | 92 | -11 | -3 | -1 | N/A |
| 6/30/2022 | 82 | 2 | 0 | 2 | N/A |
| 3/31/2022 | 77 | -3 | -9 | -1 | N/A |
| 12/31/2021 | 74 | -8 | -17 | -1 | N/A |
| 9/30/2021 | 77 | -20 | -18 | -1 | N/A |
| 6/30/2021 | 77 | -31 | -21 | -5 | N/A |
| 3/31/2021 | 80 | -28 | -6 | 5 | N/A |
| 12/31/2020 | 79 | -19 | -1 | 0 | N/A |
| 9/30/2020 | 69 | -9 | 1 | 1 | N/A |
| 6/30/2020 | 64 | -7 | 1 | 1 | N/A |
| 3/31/2020 | 56 | -5 | -3 | -2 | N/A |
| 12/31/2019 | 47 | -4 | N/A | 0 | N/A |
| 9/30/2019 | 45 | -3 | N/A | 0 | N/A |
| 6/30/2019 | 36 | -6 | N/A | -1 | N/A |
| 3/31/2019 | 25 | -5 | N/A | -1 | N/A |
| 12/31/2018 | 17 | -5 | N/A | -2 | N/A |
| 9/30/2018 | 9 | -5 | N/A | -1 | N/A |
| 6/30/2018 | 8 | -2 | N/A | -2 | N/A |
| 3/31/2018 | 8 | -3 | N/A | -3 | N/A |
| 12/31/2017 | 8 | -3 | N/A | -3 | N/A |
| 9/30/2017 | 7 | -3 | N/A | -4 | N/A |
| 6/30/2017 | 6 | -3 | N/A | -4 | N/A |
| 3/31/2017 | 5 | -1 | N/A | -1 | N/A |
| 12/31/2016 | 4 | 1 | N/A | 1 | N/A |
| 9/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 6/30/2016 | 3 | 1 | N/A | 1 | N/A |
| 3/31/2016 | 3 | -2 | N/A | -1 | N/A |
| 12/31/2015 | 3 | -4 | N/A | -3 | N/A |
| 9/30/2015 | 2 | -4 | N/A | -3 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: MDPは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3% ) よりも高い成長率であると考えられます。
収益対市場: MDP今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。
高成長収益: MDP今後 3 年以内に収益を上げることが予想されます。
収益対市場: MDPの収益 ( 14.2% ) Canadian市場 ( 4.9% ) よりも速いペースで成長すると予測されています。
高い収益成長: MDPの収益 ( 14.2% ) 20%よりも低い成長が予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: MDPの 自己資本利益率 は、3年後には高くなると予測されています ( 32 %)
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/24 00:05 |
| 終値 | 2026/07/24 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2026/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Medexus Pharmaceuticals Inc. 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10
| アナリスト | 機関 |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |